Top Page
Bio-Gene Technology Ltd.
(Sydney:BGT)
Bio-Gene Technology Ltd. (BGT) vs. iShares MSCI Australia ETF (EWA)
Bio-Gene Technology Ltd. Business Overview & Revenue Model
Bio-Gene Technology Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 18.32K | 149.23K | 445.73K | 62.61K |
| Gross Profit | -455.26K | -245.78K | -301.45K | -164.04K | 178.59K | -110.59K |
| EBITDA | -2.03M | -2.58M | -2.97M | -3.14M | -2.92M | -2.85M |
| Net Income | -2.02M | -2.58M | -2.41M | -3.10M | -2.91M | -2.40M |
Balance Sheet | ||||||
| Total Assets | 2.15M | 2.15M | 3.16M | 3.84M | 7.30M | 5.00M |
| Cash, Cash Equivalents and Short-Term Investments | 1.14M | 1.14M | 2.21M | 2.99M | 6.34M | 3.93M |
| Total Debt | 51.21K | 51.21K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 522.98K | 522.98K | 368.45K | 613.88K | 1.03M | 754.57K |
| Stockholders Equity | 1.63M | 1.63M | 2.79M | 3.22M | 6.27M | 4.25M |
Cash Flow | ||||||
| Free Cash Flow | -1.71M | -2.54M | -2.76M | -3.28M | 36.67K | -1.83M |
| Operating Cash Flow | -1.71M | -2.54M | -2.75M | -3.28M | 43.52K | -1.83M |
| Investing Cash Flow | 0.00 | 0.00 | -5.70K | 0.00 | -6.84K | -3.03K |
| Financing Cash Flow | 1.47M | 1.47M | 1.98M | -75.00K | 4.41M | 239.88K |
Bio-Gene Technology Ltd. Technical Analysis
Bio-Gene Technology Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$4.22M | -1.12 | ― | ― | -99.31% | 90.20% | |
44 Neutral | AU$8.27M | -17.46 | -8.72% | ― | ― | 71.10% | |
41 Neutral | AU$7.63M | -2.05 | ― | ― | ― | ― | |
40 Underperform | AU$2.17M | -4.33 | -28.49% | ― | ― | 46.43% | |
37 Underperform | AU$13.77M | -1.61 | -628.72% | ― | ― | 31.87% |
Bio-Gene Technology Ltd. Corporate Events
Bio-Gene Technology Ltd. has provided an update on its two projects supported by A$3.0 million in US Department of Defense grants under the Deployed Warfighter Protection program. The Flavocide wearable device project, designed to protect against mosquitoes, is progressing, with initial trials showing promising results. The Qcide indoor spray project, targeting pests like bed bugs and houseflies, is set to commence in 2026 following recent delays. These programs highlight the company’s focus on addressing the rise of insect-borne diseases with innovative, nature-based solutions for both military and civilian use.
Bio-Gene Technology Limited has completed a review of its continuous disclosure procedures following a directive from the ASX. The review led to the revision of its Communication and Disclosure Policy, the implementation of a comprehensive pre-clearance process for scientific data, and enhanced compliance training for key personnel. These measures aim to ensure that market-sensitive information is disclosed appropriately, maintaining compliance with ASX Listing Rules and enhancing the company’s operational transparency.
Bio-Gene Technology Limited has received a $519,500 research and development tax incentive from the Australian Taxation Office, reflecting its significant R&D expenditure in the 2025 financial year. This incentive supports the development of Bio-Gene’s innovative insecticides, Flavocide® and Qcide®, which are designed to target insects with a new mode of action, enhancing the company’s position in global markets and addressing the challenges of insecticide resistance.
Bio-Gene Technology Limited announced that all resolutions were passed at their 2025 Annual General Meeting. This outcome supports the company’s strategic initiatives and governance, potentially strengthening its market position in developing innovative pest management solutions. The approval of resolutions, including the re-election of a director and additional issuance capacity, reflects shareholder confidence and may positively impact future operations.
Bio-Gene Technology Ltd. held its Annual General Meeting on November 19, 2025, where it presented its ongoing efforts in developing natural insecticides. The company emphasizes its commitment to creating innovative pest control solutions with a significant global impact, aiming to strengthen its position in the biotechnology industry and offer valuable alternatives to stakeholders.
Bio-Gene Technology Ltd. reported significant progress in developing and commercializing their insecticidal products, Flavocide® and Qcide®. The company has advanced regulatory studies for Flavocide and achieved pilot-scale manufacturing success, while Qcide has been approved for listing by the Organic Materials Review Institute in the U.S. These developments strengthen Bio-Gene’s position in the pest control market, with ongoing partnerships and grants supporting their growth. The company is poised for further expansion, focusing on regulatory studies, formulation development, and market entry strategies.
Bio-Gene Technology Limited announced that its product, Qcide, has been approved by the Organic Materials Review Institute (OMRI) for listing as a Botanical Insecticide under the USDA National Organic Program. This approval enhances Bio-Gene’s market positioning by allowing Qcide to be used in organic and sustainable pest control markets, expanding its potential customer base. The listing supports Bio-Gene’s strategy of offering environmentally responsible products and opens new commercial opportunities in the growing organic agriculture and eco-label markets.
Bio-Gene Technology Limited reported significant progress in Q1 FY26, including strategic reviews and new opportunities for its products Flavocide and Qcide. The company identified additional product applications and engaged with new commercial partners, enhancing its market positioning. Notable achievements include positive efficacy results for Flavocide, the commencement of development programs funded by the US Department of Defense, and successful capital raising efforts. These developments are expected to accelerate market entry timelines and enhance revenue generation opportunities.
Bio-Gene Technology Limited is addressing a breach of ASX Listing Rule 3.1 regarding the disclosure of material information from collaborative research. The ASX found that Bio-Gene failed to disclose information promptly, leading to a review of their disclosure procedures. In response, Bio-Gene plans to strengthen protocols for managing third-party research, improve internal procedures for disclosure assessments, and provide targeted training on confidentiality and disclosure timing.
Bio-Gene Technology Ltd. has announced its 2025 Annual General Meeting (AGM) will be held virtually on November 19, 2025. The company emphasizes the importance of electronic communication to enhance sustainability and efficiency, encouraging shareholders to register for the online meeting platform to participate in real-time voting and discussions. This move reflects Bio-Gene’s commitment to modernizing shareholder engagement and reducing environmental impact.
Bio-Gene Technology Ltd has announced that its Annual General Meeting (AGM) will be held on November 19, 2025. The company is inviting nominations for director positions, with a submission deadline of October 2, 2025. This meeting is significant for stakeholders as it may influence the company’s strategic direction and governance, impacting its operations and market positioning.